NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients who do not respond to current therapies. Its lead candidates include SIM0505, a CDH6-targeted ADC licensed from Simcere Zaiming with a proprietary TOPOi payload, and LNCB74, a B7-H4-targeted ADC developed with LigaChem Biosciences using an MMAE tubulin inhibitor payload, targeting solid tumors including ovarian, breast, and endometrial cancers.
expected 2026-12-03
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001104659-26-024137 | EDGAR | 79K words |
| 2025-03-06 | 2024-12-31 | 0001558370-25-002402 | EDGAR | 74K words |
| 2024-03-21 | 2023-12-31 | 0001558370-24-003672 | EDGAR | 73K words |
| 2023-03-02 | 2022-12-31 | 0001558370-23-002698 | EDGAR | 76K words |
| 2022-03-03 | 2021-12-31 | 0001558370-22-002824 | EDGAR | 80K words |
| 2021-03-04 | 2020-12-31 | 0001558370-21-002384 | EDGAR | 81K words |
| 2020-03-12 | 2019-12-31 | 0001558370-20-002566 | EDGAR | 80K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001104659-26-092050 | EDGAR | 22K words |
| 2025-11-05 | 2025-09-30 | 0001104659-25-107036 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010782 | EDGAR | 18K words |
| 2025-05-01 | 2025-03-31 | 0001558370-25-006111 | EDGAR | 14K words |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014869 | EDGAR | 15K words |
| 2024-08-01 | 2024-06-30 | 0001558370-24-010605 | EDGAR | 15K words |
| 2024-05-02 | 2024-03-31 | 0001558370-24-006551 | EDGAR | 14K words |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017429 | EDGAR | 15K words |
| 2023-08-03 | 2023-06-30 | 0001558370-23-013250 | EDGAR | 15K words |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008131 | EDGAR | 13K words |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016275 | EDGAR | 15K words |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012232 | EDGAR | 15K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-25 | 0001104659-26-110971 | EDGAR | 5K words |
| 2026-09-03 | 0001104659-26-105057 | EDGAR | 2K words |
| 2026-08-06 | 0001104659-26-092025 | EDGAR | 3K words |
| 2026-07-14 | 0001104659-26-083326 | EDGAR | 3K words |
| 2026-03-05 | 0001104659-26-024121 | EDGAR | 2K words |
| 2026-01-23 | 0001104659-26-006021 | EDGAR | 3K words |
| 2025-12-19 | 0001104659-25-123305 | EDGAR | 22K words |
| 2025-11-17 | 0001104659-25-112975 | EDGAR | 1K words |
| 2025-11-05 | 0001104659-25-107008 | EDGAR | 2K words |
| 2025-08-25 | 0001558370-25-011752 | EDGAR | 1K words |
112 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001661059 |
| Ticker | NXTC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nextcure.com |
| Listed | 2019-05-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NXTC (~200 tokens, structured JSON with cryptographic provenance)